INTRODUCTION
Newly synthesized secretory and membrane proteins that do not pass quality control at the endoplasmic reticulum (ER) are typically retained by resident chaperones and routed to ER-associated degradation (ERAD) pathways (Hegde and Ploegh, 2010) . Under some conditions, the burden of nascent unfolded and misfolded proteins in the ER increases beyond its processing capacity, leading to ER stress (Schrö der and Kaufman, 2005) . This activates the unfolded protein response (UPR), a multipronged signaling pathway that transcriptionally upregulates factors involved in expanding the ER protein folding capacity (Ron and Walter, 2007) .
Although the UPR can restore protein folding homeostasis, the temporal lag of the transcriptional response (typically hours) raises the question of how protein quality control is achieved for misfolded proteins present in the ER during the acute phase of ER stress. Although the simplest answer is degradation by ERAD, these pathways would likely be temporarily saturated. Furthermore, recent work on mammalian prion protein (PrP) has suggested that at least some misfolded proteins may not be good substrates for ERAD.
PrP is a widely expressed cell surface glycosylphosphatidylinositol (GPI) anchored protein. Although the normal function of PrP is uncertain, its misfolding is causative of various diseases (Aguzzi et al., 2008; Prusiner, 1998) . Among these, numerous natural and artificial misfolding or mislocalization mutants lead to neurodegeneration in both mice and humans (Ková cs et al., 2002) . Despite the importance of PrP misfolding in disease, the various pathways of misfolded PrP degradation are not well established.
Intriguingly, many PrP mutants that enter the ER lumen were found to be poorly degraded by ERAD, apparently relying instead on lysosomes (Ashok and Hegde, 2009) . A notable exception was the situation in which addition of PrP's GPIanchor was blocked by either mutation or genetic perturbation, in which case the unprocessed PrP was routed efficiently for ERAD (Ashok and Hegde, 2008) . These observations hinted at the possibility that GPI-anchored misfolded PrP was degraded by an undefined non-ERAD route. Such a pathway might be especially important during ER stress, a frequently encountered condition in vivo, including during PrP-induced neurodegeneration (Hetz and Soto, 2006) . These considerations motivated us to investigate the fate of misfolded PrP along with other unrelated misfolded GPI-anchored proteins during acute ER stress.
Our experiments led us to a heretofore unappreciated pathway that clears a diverse range of misfolded GPI-anchored proteins from the ER within minutes of ER stress. These misfolded proteins synchronously enter the secretory pathway and briefly transit the plasma membrane before their final targeting to lysosomes for destruction. Knockdown of the major ER export factor, Tmp21, prevents this stress-induced egress, resulting in misfolded protein aggregation in the ER. The wide conservation of the GPI anchor in all eukaryotes and the fact that mammals express more than 150 different GPI-anchored proteins of critical function (Fujita and Kinoshita, 2012) highlight the importance of our findings.
RESULTS

Stress-Induced Clearance of ER-Retained Misfolded PrP for Lysosomal Degradation
We created a constitutively misfolding variant of PrP, hereafter named PrP*, by perturbing the essential disulfide bond between cysteine residues 179 and 214 with a C179A point mutation ( Figure 1A ). PrP* was fluorescent protein (FP) tagged at a site previously shown not to disrupt wild-type PrP folding or trafficking (Ashok and Hegde, 2009) . Our construct was equipped with the prolactin signal sequence to ensure efficient translocation into the ER (Kang et al., 2006) and stably expressed in cultured cells at physiological levels (Figure S1A available online). In contrast to cell-surface localized wild-type YFP-PrP, constitutively misfolded YFP-PrP* was almost entirely retained in the ER at steady state in multiple cell types (Figures 1B, S1B, and S1C).
Upon application of two independent ER stressors, thapsigargin (TG) and dithiothreitol (DTT), live-cell time-lapse imaging revealed rapid relocalization of YFP-PrP* from the ER to a perinuclear locale (within 10-30 min), distributed puncta (within 30-60 min), and disappearance from those puncta (by 60-120 min) ( Figure 1C and Movies S1 and S2). Biochemical analysis of radiolabeled YFP-PrP* verified that acute ER stress accelerates its degradation relative to untreated cells ( Figure 1D ). As we discovered later (see below), untreated cells also employ the same degradation pathway at low levels, explaining why50% of YFP-PrP* is lost by 90 min. Similar stressenhanced degradation was observed for other disulfide mutants of PrP, including C179S, C214A, or C214S (data not shown) and human disease mutants of PrP (described below). Thus, misfolded PrPs residing in the ER at the onset of acute ER stress are rapidly degraded by a pathway involving its relocalization.
An inhibitor of secretory traffic, brefeldin A (BFA) (Klausner et al., 1992) , blocked the ER-stress-induced relocalization of PrP*, suggesting that ER export was involved (Figure 2A ). Colocalization experiments at different times after stress induction showed that YFP-PrP* transits successively through the ER, ER exit sites, ER-Golgi intermediate compartment, Golgi, and lysosomes ( Figure 2B ). YFP-PrP* followed the same itinerary in multiple cell types derived from different tissues (Figures S1B and S1C).
Quantitative microscopy of the trafficking pathway that YFPPrP* followed during ER stress revealed that more than 80% of the protein resided solely in post-ER compartments prior to being degraded ( Figure S1D ). This suggests that ERAD pathways are not a major determinant of PrP* degradation during ER stress. Instead, its lysosomal localization prior to disappearance indicated that lysosomes are the major site of PrP* degradation (Figures 2B and 2C) . Interfering with lysosomal function by inhibiting either its resident proteases or its acidification (with bafilomycin A1) increased PrP* accumulation in lysosomes ( Figures 2C and S2A-2C ). Immunoblotting analysis verified that full-length YFP-PrP* was indeed stabilized with BFA, lysosomal inhibitor, or bafilomycin A1 treatments ( Figures 2D  and S2D ).
Of note, we determined that autophagy does not play a role in relocalization of YFP-PrP* to lysosomes by using bafilomycin A1, which blocks autophagosome fusion with lysosomes in addition to inhibiting lysosomal degradation (Yamamoto et al., 1998) . YFP-PrP* accumulated within lysosomes rather than in autophagosomes under these conditions ( Figure S2E ). Furthermore, inhibition of autophagy with 3-methyladenine had no effect on PrP* relocalization to lysosomes (data not shown).
These results reveal a stress-induced process for export of misfolded ER-retained proteins to downstream compartments of the secretory pathway for subsequent lysosomal degradation. We term this ER-clearance process RESET (for rapid ER stress-induced export) to distinguish it from qualitatively different ER-clearance pathways that involve ERAD or autophagy.
Misfolded PrP Accesses the Cell Surface during Transit to Lysosomes
Trafficking to lysosomes can either be direct from the Golgi or indirect via the plasma membrane (Arvan et al., 2002; Luzio et al., 2003) . To see whether YFP-PrP* accesses the cell surface en route to lysosomes, we inhibited the major endocytosis pathways with the cholesterol-depleting agent methyl-b-cyclodextrin (MbCD) (Kirkham and Parton, 2005; Rodal et al., 1999) . When YFP-PrP* molecules were released from the ER with stress in the presence of MbCD, a substantial proportion of these molecules was observed to be trapped at the plasma membrane ( Figure 3A ) and accessible to extracellular antibody ( Figure 3B ). Antibody uptake assays in the absence of MbCD verified that stress-released YFP-PrP* that ultimately arrived in lysosomes had sampled the cell surface ( Figure 3C ). Its apparent short residence time at the plasma membrane relative to wild-type PrP ( Figure 1B) implicates poorly understood quality control pathways at the plasma membrane for selective internalization and destruction in lysosomes.
Diverse Misfolded GPI-Anchored Proteins Access the RESET Pathway The ER-retained T cell receptor subunit, CD3d, was not exported during acute ER stress ( Figure 4A ) and instead was degraded by ERAD (Klausner et al., 1990) . This suggested that RESET may be dependent on a feature of the ER quality control substrate. Domain analysis of YFP-PrP* revealed that one element regulating its RESET is the GPI anchor. Either preventing GPI-anchor addition (with the processing site mutation S232W [Ashok and Hegde, 2008] ) or deleting the GPI-anchoring signal resulted in an ER-retained misfolded protein that was not exported to downstream compartments of the secretory pathway during stress ( Figure 4B ). By contrast, RESET was unaffected by preventing N-linked glycosylation of YFP-PrP* (with mutations to both asparagines, N181T and N197T) ( Figure 4B ) or eliminating the YFP-tag ( Figure S3A ).
We tested whether the GPI anchor may be a general signal to route misfolded proteins for RESET by examining artificial and naturally occurring mutants of GPI-anchored proteins whose GFP-tagged wild-type versions traffic normally to the plasma membrane ( Figure 4C ). The ER-retained pool of disulfide mutants of three unrelated GPI-anchored proteins-CD59, Thy1, and DAF-underwent RESET ( Figure 4D ). Importantly, RESET was not limited to artificial mutants but also was seen with several human disease-associated mutants ( Figures 4E and S3B ). These include the D202N and F198S mutants in PrP (Gu et al., 2007; Ivanova et al., 2001) , the C89Y mutant in CD59 (Nevo et al., 2013) , and the C65W mutant in folate receptor 1 (Grapp et al., 2012) . These results suggest that GPI-anchored proteins represent a major client set for RESET.
This conclusion is consistent with old observations on the fate of the transmembrane TCR-a, an unassembled T cell receptor subunit and ERAD substrate (Suzuki et al., 1991) . Although a soluble truncated version of TCR-a lacking the cytosolic and transmembrane domains (TCR-a t ) was found to be retained in the ER in thapsigargin-treated cells, a variant in which TCR-a t is appended to a GPI-anchor (TCR-a GPI ) is exported to the cell surface. We verified this result and found that RESET of TCR-a GPI is seen with either thapsigargin-or DTT-mediated ER stress ( Figure S3C ). Thus, an ERAD substrate can be converted to a RESET substrate solely by the addition of a GPI-anchor, identifying this as at least one major feature of a RESET client.
RESET Clients Utilize Tmp21-Mediated ER Export
We next determined the mechanistic basis of RESET. RESET presumably operates by switching from retention of the mis- folded protein in the ER under nonstressed conditions to egress during ER stress. This implies the existence of a retention factor and an export receptor. A candidate retention factor for YFPPrP* was identified by immunoprecipitation and mass spectrometry. In these experiments, we looked for ER-resident interaction partners that release very shortly after application of ER stressors. An 90 kD band first detected in radiolabeled coimmunoprecipitation experiments ( Figures S4A-S4F ) was identified by mass spectrometry as calnexin, an ER-resident chaperone (Bergeron et al., 1994) . The reliance on a GPI-anchor for RESET of YFP-PrP* implicated the p24 family of export receptors for GPI-anchored protein trafficking (Bonnon et al., 2010; Schimmö ller et al., 1995; Takida et al., 2008) . We therefore scrutinized these factors for their potential role in RESET.
Coimmunoprecipitation experiments showed that calnexin associates with YFP-PrP*, but not as strongly with wild-type YFPPrP, suggesting a misfolding-dependent interaction ( Figures 5A  and S4C ). The p24 family member, Tmp21, interacted with both misfolded and wild-type PrPs ( Figure 5A ). By contrast, the unrelated ER export receptor ERGIC53 showed no interaction with either YFP-PrP* or YFP-PrP, providing a specificity control. The interactions with Tmp21 and calnexin were strongly dependent on the GPI anchor ( Figure 5B ), which is consistent with their potential role in RESET.
Upon induction of ER stress, the interaction with calnexin was lost, whereas the Tmp21 interaction was maintained (Figure 5C ). YFP-PrP* egress proved to be dependent on Tmp21, as evidenced by a strong failure in RESET in Tmp21 knockdown cells ( Figures 5D-5F ). Similarly, calnexin and Tmp21 interaction were observed for misfolded CD59 ( Figure S4G ), and dependence on Tmp21 for stress-induced ER export was shown for CD59 ( Figure S4H ) and TCR-a GPI ( Figure S4I ). Collectively, these results demonstrate that Tmp21 plays a key role in the RESET of misfolded GPI-anchored proteins.
Notably, wild-type PrP and CD59 showed no gross defects in their steady-state plasma membrane localization in Tmp21 knockdown cells (Figures 5D and S4H ). This is consistent with an earlier study that showed only a mild kinetic delay in wild-type GPI-anchored protein trafficking in the absence of Tmp21 (Takida et al., 2008) . The far stronger dependence on Tmp21 for misfolded GPI-anchored protein ER export implicates a role for Tmp21 in maintenance of ER protein folding homeostasis. 
ER Stress Drives Aggregation of Misfolded PrP in the ER of Tmp21-Depleted Cells
To clarify the physiologic role of RESET in maintaining ER homeostasis, we depleted Tmp21 and assessed the biochemical and biophysical properties of ER-retained PrP*. YFP-PrP* in unstressed Tmp21 knockdown cells was associated with calnexin by coimmunoprecipitation ( Figure 6A ) and is predominantly soluble in nondenaturing detergents ( Figure 6B ). Upon ER stress, the calnexin interaction was lost ( Figure 6A ), despite the fact that YFP-PrP* does not exit the ER in Tmp21 knockdown cells (Figures 5D-5F ). This loss of chaperone interaction was accompanied by YFP-PrP* becoming substantially detergent insoluble ( Figure 6B ), suggesting that it had partially aggregated.
In cells containing Tmp21, YPF-PrP* would exit the ER upon ER stress, thereby escaping aggregation in the ER. To test whether YFP-PrP* aggregation in Tmp21 knockdown cells was simply a consequence of preventing this exit, we analyzed control cells subjected to ER stress in the presence of BFA to prevent ER export ( Figure 6C ). Instead of aggregating, YFP-PrP* remained largely soluble under these conditions. This suggests that Tmp21, beyond simply exporting YFP-PrP* out of a stressed ER, plays a role in precluding its aggregation. Such a function for Tmp21 may be due to its direct interaction with YFP-PrP*, although this remains to be examined in future studies.
In addition to the biochemical analysis, we studied the diffusion properties of YFP-PrP* in live cells using fluorescence recovery after photobleaching (FRAP) (Figures 6D and 6E) . YFP-PrP* in the ER of unstressed cells, with or without Tmp21 knockdown, displayed rapid diffusion with a t 1/2 of fluorescence recovery of 3 s. By contrast, YFP-PrP* in the stressed ER of Tmp21 knockdown cells had a nearly 5-fold slower recovery rate with a t 1/2 of 14 s. Importantly, ER stress caused at most a modest change in mobility for YFP-CD3d, YFP-PrP*, or wildtype YFP-PrP retained in the ER by BFA ( Figures 6E and S5A-S5C ). Thus, a dramatic reduction of diffusion is selective to the RESET substrate PrP* and depends on the triad of ER stress, Tmp21 depletion, and PrP misfolding.
The results from the solubility assays and FRAP analyses are consistent with a model wherein Tmp21-mediated RESET is critical for avoiding PrP* aggregation in the ER during ER stress (Figure S5D) . Accordingly, in wild-type cells, most PrP* is maintained in a soluble state through its interaction with ER chaperones, whereas under acute ER stress conditions, when chaperone availability is limiting, PrP* can bind to Tmp21. Tmp21-PrP* interaction fulfills two parallel functions: (1) maintaining PrP* in a soluble state and (2) facilitating PrP* export from the ER. In support of this model, Tmp21 depletion leads to PrP* retention in the ER and its aggregation in stressed cells, whereas in cells in which Tmp21 is available, PrP* that is retained in the ER by BFA treatment does not aggregate with stress.
Relationship between RESET and the Unfolded Protein Response
To explore the relationship between RESET and the UPR, we generated a YFP-PrP*-expressing cell line that was stably transfected with an XBP1-mCherry reporter for UPR induction (Brunsing et al., 2008) . ER stress activates Ire1 to initiate the UPR by splicing XBP1 mRNA, allowing for expression of the XBP1 transcription factor (Yoshida et al., 2001 ). Therefore, we could simultaneously monitor in live cells the RESET of PrP* and the ER stress response, as revealed by XBP1-mCherry fluorescence.
Induction of ER stress at a point when most YFP-PrP* was in the ER triggered RESET of YFP-PrP* within minutes, whereas XBP1-mCherry was detectably produced starting at 3 hr ( Figures  7A and S6A) . UPR induction was maximal from between 4 and 10 hr, after which it declined. Remarkably, localization of PrP* began reverting to the ER within 3.5 hr, and after 10 hr, PrP* predominantly localized to the ER. Thus, RESET appears to be most active during the window of time when ER function is compromised and before the cell has compensated via UPR action. After UPR-mediated gene expression begins to restore ER homeostasis, most of the PrP* is again found to be retained in the ER. 
Degradation of Misfolded GPI-Anchored Proteins in Cells without Exogenous Stressors
Given that misfolded GPI-anchored proteins appear to be poor ERAD clients, we investigated their degradation in the absence of acute ER stress. Three experiments suggested that their degradation culminates in lysosomes by a pathway similar to RESET. First, treatment of YFP-PrP*-expressing cells with MbCD resulted in its trapping at the plasma membrane (Figure 7B) . Second, antibody uptake experiments illustrated that, even without ER stress, YFP-PrP* accesses the extracellular space at least transiently (data not shown). And third, inhibition of lysosomal proteases resulted in YFP-PrP* accumulation in puncta that colocalized with a lysosomal marker ( Figure 7C ). Thus, although constitutive degradation of PrP* occurs at a slower rate in unstressed cells such that most of the YFPPrP* is ER localized, the constitutive degradation pathway shares with RESET the trafficking itinerary as well as the final destination.
Insight into the relationship between the stress-induced and steady-state degradation pathways came from careful examination of YFP-PrP* trafficking upon induction of its expression. We observed that, shortly after transient transfection, most of the newly synthesized YFP-PrP* was evidently undergoing RESET as judged by its post-ER localization ( Figure 7D and Movie S3). At longer times after transient transfection, the cells attained a new steady state in which most of the increased load of PrP* could be localized to the ER ( Figures 7C and 7E and Movie S3). This phenomenon could be explained by the possibility that transient expression of a misfolded protein is itself an ER stressor. Indeed, detecting transcription factors downstream of UPR stress transducers ( Figure 7F ) or using a luciferase reporter of UPR activation revealed that induction of YFP-PrP* or any of several other PrP mutants caused ER stress (Figures S6B-6D ). The level of luciferase reporter activation was roughly similar to that observed with 0.5 to 1 mM DTT ( Figure S6D ). This explains why, at short times after transfection, YFP-PrP* undergoes RESET, whereas at later time points, adaptation of cells via UPR induction allows cells to achieve a new steady state in which PrP* is predominantly localized to the ER.
It is worth noting that, in the adapted state, YFP-PrP* is still being exported for lysosomal degradation via the secretory pathway. This can be rationalized by considering that binding and release from ER chaperones is in competition with alternative fates (Sekijima et al., 2005) , such as binding to export receptors like Tmp21. Thus, the balance may favor chaperones at steady state but may shift strongly toward export when chaperone function is overwhelmed or compromised as during ER stress. Furthermore, even though the cells have adapted to YFP-PrP* expression via UPR induction, they are nevertheless still susceptible to additional stressors that act globally by perturbing the folding of other proteins, explaining why YFP-PrP* in adapted cells is rapidly routed for RESET with subsequent DTT or thapsigargin treatment.
DISCUSSION
Our findings have revealed a previously unappreciated pathway for degradation of misfolded GPI-anchored proteins that represents a protective mechanism to alleviate acute ER stress. By allowing a subset of misfolded proteins to engage cargo receptors, the burden of misfolded proteins in the ER is rapidly reduced and aggregation is avoided. In the case of the GPI-anchored proteins studied here, the primary mechanism of ER retention is an association with calnexin, whereas the primary mechanism of egress depends on the ER export receptor Tmp21. Interestingly, whereas folded GPI-anchored proteins can clearly use Tmp21-independent routes for ER export (Bonnon et al., 2010; Takida et al., 2008) , misfolded GPI-anchored proteins seem to be strongly dependent on Tmp21. This may explain the constitutive ER stress phenotype seen in Tmp21-deficient cells of Drosophila and yeast (Belden and Barlowe, 2001; Boltz and Carney, 2008; Jonikas et al., 2009 ) and the early embryonic lethality of Tmp21 knockout mice (Denzel et al., 2000) .
The discovery that ER stress triggers the dramatic escape of misfolded, GPI-anchored proteins from the ER to the Golgi was unexpected. Most other reports show that treatment with ER stressors results in tight binding of ER-localized proteins to ER chaperones (Kim and Arvan, 1995; Ma and Hendershot, 2004) . The mechanistic basis for this difference is likely to hinge on two major determinants: a misfolded domain and a GPI anchor. Although neither the misfolded domain nor the GPI anchor is sufficient alone, they collude to permit RESET for multiple unrelated proteins through a requisite interaction with Tmp21.
Notably, the folding status of the GPI-anchored protein appeared to influence its dependence on Tmp21 for ER export. Whereas surface localization of wild-type PrP or CD59 was not appreciably affected by Tmp21 knockdown, ER export of the misfolded variants of PrP and CD59 was severely compromised. At present, the basis of this discrimination is not clear and merits further investigation. One possible explanation may be related to the observed ability of Tmp21 to prevent PrP* aggregation in the ER independently of mediating its export. Tmp21, either directly or in conjunction with other factors, maintains misfolded PrP in a soluble state. Thus, Tmp21 may act as a chaperone to bind misfolded GPI-anchored proteins, preventing inappropriate interactions and ensuring safe passage through the secretory pathway en route to lysosomes.
Tmp21 is a type 1 transmembrane protein that cycles between the ER and Golgi and contains a cytosolic COPII binding signal (Blum et al., 1996; Dominguez et al., 1998; Nickel et al., 1997) . Thus, Tmp21-mediated ER export of GPI-anchored proteins could be explained by its ability to bridge the gap between the GPI-anchored clients within the ER lumen and the vesicular trafficking machinery on the cytosolic side. Hence, ER retention of PrP* in Tmp21 knockdown cells could be due simply to the lack of a suitable export receptor. Although we cannot rule out the alternative explanation that failed export in Tmp21 knockdown cells is a secondary consequence of an altered ER environment, the physical interaction between Tmp21 and PrP* and previous reports suggesting that p24 proteins facilitate GPI-anchored protein ER export (Bonnon et al., 2010; Schimmö ller et al., 1995; Takida et al., 2008 ) support a more direct mechanism.
It is emerging that GPI-anchored proteins may be refractory to degradation by ERAD (Ashok and Hegde, 2009; this study) . This may be because the covalently attached lipid in the lumenal leaflet of the lipid bilayer poses a topologic problem for ERAD machinery. For example, earlier work clearly showed that a PrP mutant (H187R) containing an unprocessed GPI-anchoring signal sequence is a strong degron for ERAD, but the identical protein containing a GPI anchor is degraded in lysosomes Hegde, 2008, 2009) . Similarly, the efficient ERAD substrate TCR-a can be converted to a RESET substrate by changing it from a transmembrane protein to a GPI-anchored protein (Suzuki et al., 1991; this study) .
The difficulty in degrading misfolded PrP from the ER and its propensity to aggregate there under stress conditions may explain why multiple mechanisms have evolved to prevent its residence in the ER lumen during stress. In addition to RESET, earlier work showed that the efficiency of PrP translocation into the ER is reduced during ER stress (Kang et al., 2006) . This attenuation was dependent on the PrP signal peptide and, when bypassed, led to its increased propensity to aggregate inside the ER. Thus, by a combination of both clearance via RESET and attenuation of new entry, aggregation of misfolded PrP is minimized inside the ER lumen. The extent to which these mechanisms apply to other GPI-anchored proteins remains to be investigated in detail.
Stress induction simply by the expression of disease-associated PrP mutants ( Figures S6B-S6D) , combined with our discovery of a RESET pathway for lysosomal degradation, may explain why most mutant PrPs are found to be only partially retained in the ER (Ashok and Hegde, 2009; Gu et al., 2007; Ivanova et al., 2001) . We posit that the constitutive ER stress caused by mutant PrP expression activates RESET, at least partially, leading to mutant PrP egress via the secretory pathway. Indeed, knockdown of Tmp21 leads to increased ER retention of mutant PrP, but not wild-type PrP, at steady state. The net consequence of these effects would be a highly heterogeneous distribution of mutant PrP in the secretory pathway, constitutive ER stress, overall reduced plasma membrane localization, and primarily lysosomal degradation. This is precisely the picture of mutant PrP behavior deduced from multiple earlier analyses (Ashok and Hegde, 2009; Gu et al., 2007; Ivanova et al., 2001; Negro et al., 2001) .
The transient appearance of PrP* on the plasma membrane followed by rapid endocytosis and delivery to lysosomes implicates post-ER quality control pathways for the disposal of misfolded proteins released from the ER by RESET. At present, the mechanisms that permit the cell to distinguish folded from misfolded GPI-anchored proteins at the plasma membrane (or Golgi) are unknown. Although plasma membrane quality control has been described for the integral membrane proteins CFTR (Okiyoneda et al., 2010) , an artificially constructed thermolabile substrate (Apaja et al., 2010) , and a panel of thermolabile mutant transporters (Zhao et al., 2013) , in each case, cargo recognition begins with ubiquitination on the misfolded cytosolic domain. GPI-anchored proteins lack a cytosolically exposed domain. Thus, understanding how noncytosolic defects in proteins can be detected in post-ER compartments remains an important goal for future studies aimed at clarifying the downstream fate of proteins undergoing RESET.
Our studies initially revealed and characterized RESET by using chemical stressors. However, several observations argue for this pathway's relevance in physiological situations. First, GPIanchored proteins are abundant and ubiquitous (Ferguson et al., 2009 ) with many known disease-causing misfolding variants (Grapp et al., 2012; Gu et al., 2007; Ivanova et al., 2001; Nevo et al., 2013) . Given that diverse misfolded GPI-anchored proteins undergo RESET in multiple cell types, RESET is likely to be a widely used mechanism for the clearance of misfolded GPI-anchored proteins from the ER. Second, cells commonly experience any of a variety of physiological acute stressors such as viral infection (Diehl et al., 2011) , ischema (Perman et al., 2011) , and differentiation (Reimold et al., 2001) , where RESET may act to ameliorate the imbalance in ER homeostasis prior to UPR-mediated adaptation. This idea is supported by our demonstration that new expression of PrP* alone, at physiological levels without additional chemical stressors, induces acute ER stress sufficient to induce RESET of PrP*. Subsequently, the UPR is triggered in PrP*-expressing cells, which likely leads to a new homeostasis, as indicated by the eventual retention of most of the PrP* in the ER. Third, in cells that have adapted to PrP* expression, the export pathway to lysosomes was utilized at low levels by PrP* for constitutive degradation.
The rate of engagement of the RESET pathway is predicted to be contingent on the dynamics of interaction between ER resident chaperones and ER export receptors. This is presumably a continuum and is dependent on both the substrate in question and homeostatic state of the ER (Sekijima et al., 2005) . In this view, RESET is an enhanced version of a degradation pathway that occurs at more modest levels in the absence of exogenous stressors. This is analogous to other aspects of ER stress responses, where physiologic changes in flux through the ER induce modest changes in the same pathways that were first discovered using artificial reporters and chemical stressors (e.g., ERAD [Bonifacino and Lippincott-Schwartz, 1991] or the UPR [Ma and Hendershot, 2001] ). Our conceptual description of RESET, along with the detailed characterization of Tmp21-dependent RESET for GPI-anchored proteins, provides a foundation for future exploration of its different physiologic and pathophysiologic roles.
EXPERIMENTAL PROCEDURES
Detailed methods are provided in the Extended Experimental Procedures.
Cells, Plasmids, and siRNA All experiments were performed in stably transfected normal rat kidney (NRK) cells, unless specified. All cells cotransfected with organelle markers were imaged 48 hr after transient transfection. YFP-PrP was constructed by replacing the endogenous PrP signal sequence (residues 1-22) with the bovine preprolactin-signal sequence to ensure efficient translocation into the ER (Rane et al., 2004) and inserting mYFP into the unique Bsu36I site. Construction of eGFP-CD59, GFP-Thy1, GFP-DAF, and GFP-FolR is described in the Extended Experimental Procedures. Misfolding mutants were derived by site-directed mutagenesis. Tmp21 was depleted by two sequential knockdowns within 48 hr using 50 nM concentration of ON-TARGETplus SMARTpool Rat Tmed10 siRNA and Dharmafect 2 transfection reagent (Dharmacon), and experiments were performed 24 hr after the second knockdown.
Drug Treatments
Working concentrations are 0.1 mM thapsigargin, 0.5 mM dithiothreitol, 5 mM methyl-b-cyclodextrin, and 1 mM brefeldin A. Lysosomal protease inhibitors refer to 125 mM leupeptin + protease inhibitor cocktail (Sigma P8340) diluted 1:100.
Microscopy
All fixed and live-cell imaging, excluding FRAP, were performed using the Marianas spinning disk confocal system (Intelligent Imaging Innovations) attached to a Zeiss Observer.Z1 microscope (Carl Zeiss MicroImaging) and analyzed by Slidebook software. FRAP was performed and analyzed with the Zeiss LSM 710 system (Carl Zeiss MicroImaging).
Biochemistry
For steady-state chase experiments, cells were labeled for 10 hr with 100 mCi/ml 35 S label (NEG072002MC, Perkin Elmer) in Cys-free/Met-free media (D0422, Sigma) supplemented with 10% serum, 2 mM L-Glu, 0.6 mM Cys, and 2 mM Met. Column purifications were performed with the mMACS GFP Isolation Kit (Miltenyi Biotec) using 1% CHAPS, 50 mM HEPES (pH 7.4), and 100 mM NaCl for cell lysis and washes. 
SUPPLEMENTAL INFORMATION
